Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes From Study P-2001

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 01期
关键词：
NEDD8-ACTIVATING ENZYME; INHIBITOR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 13
页数：3
相关论文
共 50 条
  • [41] EFFICACY OF CC-486 (ORAL AZACITIDINE) TREATMENT (TX) IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
    Garcia-Manero, G.
    Savona, M. R.
    Gore, S. D.
    Conkling, P.
    Cogle, C. R.
    Hetzer, J.
    Dong, Q.
    Kumar, K.
    Ukrainskyj, S. M.
    Beach, C.
    Skikne, B. S.
    HAEMATOLOGICA, 2015, 100 : 239 - 239
  • [42] Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)
    Garcia-Manero, Guillermo
    Scott, Bart L.
    Kishtagari, Ashwin
    Sanikommu, Srinivasa R.
    Al-Kali, Aref
    Lee, Je-Hwan
    Burgues, Juan M. Bergua
    Diez-Campelo, Maria
    Erba, Harry P.
    Garcia-Hernandez, Carmen
    Santillana, Guillermo Sanz
    O'Connell, Casey
    Jang, Jun-Ho
    Shin, Dong-Yeop
    Sayar, Hamid
    Rao, Mayank
    Schwartz, Richard S.
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Tsiatis, Athanasios C.
    Altman, Jessica K.
    CANCER RESEARCH, 2024, 84 (07)
  • [43] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    Fenaux, Pierre
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    Finelli, Carlo
    Giagounidis, Aristoteles
    Schoch, Robert
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan
    Gore, Steven D.
    Seymour, John F.
    Bennett, John M.
    Byrd, John
    Backstrom, Jay
    Zimmerman, Linda
    McKenzie, David
    Beach, C. L.
    Silverman, Lewis R.
    LANCET ONCOLOGY, 2009, 10 (03): : 223 - 232
  • [44] Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
    Navada, Shyamala C.
    Silverman, Lewis R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (01) : 21 - 27
  • [45] Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
    Giulia Falconi
    Emiliano Fabiani
    Alfonso Piciocchi
    Marianna Criscuolo
    Luana Fianchi
    Elisa L. Lindfors Rossi
    Carlo Finelli
    Elisa Cerqui
    Tiziana Ottone
    Alfredo Molteni
    Matteo Parma
    Stella Santarone
    Anna Candoni
    Simona Sica
    Giuseppe Leone
    Francesco Lo-Coco
    Maria Teresa Voso
    Leukemia, 2019, 33 : 785 - 790
  • [46] EFFECT OF AZACITIDINE (AZA) ON TRANSFUSION INDEPENDENCE (TI) AND OVERALL SURVIVAL IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Seymour, J.
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Sanz, G.
    List, A. F.
    McKenzie, D.
    Backstrom, J.
    Beach, C. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 328 - 328
  • [47] TP53 MUTATIONS ARE ASSOCIATED WITH COMPLEX CYTOGENETICS IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES AND IMPACT RESPONSE TO AZACITIDINE
    Mueller-Thomas, C.
    Rudelius, M.
    Schmidt, B.
    Peschel, C.
    Platzbecker, U.
    Goetze, K.
    HAEMATOLOGICA, 2012, 97 : 363 - 363
  • [48] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [49] Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
    Seymour, John F.
    Fenaux, Pierre
    Silverman, Lewis R.
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    List, Alan F.
    Gore, Steven D.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 76 (03) : 218 - 227
  • [50] Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
    Falconi, Giulia
    Fabiani, Emiliano
    Piciocchi, Alfonso
    Criscuolo, Marianna
    Fianchi, Luana
    Rossi, Elisa L. Lindfors
    Finelli, Carlo
    Cerqui, Elisa
    Ottone, Tiziana
    Molteni, Alfredo
    Parma, Matteo
    Santarone, Stella
    Candoni, Anna
    Sica, Simona
    Leone, Giuseppe
    Lo-Coco, Francesco
    Voso, Maria Teresa
    LEUKEMIA, 2019, 33 (03) : 785 - 790
12345